Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Azacitidine in Lower-Risk MDS Shows Promise

Oncologist; ePub 2017 Nov 8; Komrokji, et al

Azacitidine appears promising in certain patients with lower-risk myelodysplastic syndrome (MDS), researchers concluded after conducting an analysis involving 233 individuals. Participants were from 6 clinical studies and 1 registry. Investigators looked at red blood cell (RBC) transfusion independence (TI) and clinical benefit. Among the results:

  • 9 in every 10 patients had non-del(5q) LR-MDS.
  • RBC-TI occurred in 39% of these individuals, and clinical benefit in 81%.
  • In patients with isolated anemia, RBC-TI and clinical benefit occurred in 42% and 83%, respectively.
  • Plans to use ≥6 azacitidine treatment cycles significantly predicted response.

The authors noted that their findings show that azacitidine works just as well as lenalidomide does in patients with similar characteristics.


Komrokji R, Swern A, Grinblatt D, et al. Azacitidine in lower-risk myelodysplastic syndromes: A meta-analysis of data from prospective studies. [Published online ahead of print November 8, 2017]. Oncologist. doi:10.1634/theoncologist.2017-0215.